The 2nd Co-creation Meeting
Event Report
Creating the Future Together with the Power of Change and Challenge
The 2nd Co-creation Meeting was held to explore new opportunities for collaboration through dialogue that transcends organizational boundaries toward the realization of "Industrial Vision 2035. Here is a report on the day-long meeting attended by 83 participants, including Chairpersons of various committees, executives, and JPMA board members.
Special Feature "Medical DX" Vol. 2
Connecting" Creates the Future
Digital and Data Pioneer the Frontiers of DX in Japanese Medicine
In order to ensure the stable delivery of pharmaceuticals, it is imperative to address human resource shortages and logistics issues. This session will explore the current transformation brought about by the co-creation of industry-academia-government from the three perspectives of "Commercial Production DX," "Pharmaceutical Distribution DX," and "Japanese Version of EHDS.
From JPMA
Interview with Managing Director Ishida
Building a Foundation of Trust and Creating Value Together
He will discuss how the pharmaceutical industry can respond to society's trust in it through a review of the definition of promotion in the 2025 revision of the Code of Practice (COP), compliance as an organizational culture, and the philosophy of "co-creation.
My Committee
vol.5 The Office of Pharmaceutical Industry Research
Introducing The Office of Pharmaceutical Industry Research, a think tank that analyzes and reviews the environment surrounding the pharmaceutical industry and medium- to long-term issues facing the industry, and makes recommendations.
The Pharmaceutical Industry from a Factual Perspective
Connecting the voices of patients with
the value of medicine and drug discovery PRO
PRO is a tool to evaluate symptoms, quality of life, treatment satisfaction, etc. directly reported by patients themselves. Four facts surrounding the utilization of PROs in Japan will unravel the need for social implementation.
Topics
Introducing various topics within the association
The JPMA's latest initiatives and activity results, including the announcement of a new collaborative framework "AND-E" with AMED to strengthen the drug discovery ecosystem and the issuance of the "Clinical Trial Ecosystem Industry Declaration 2025," which aims to improve international competitiveness.
Please click here to send us your comments on the renewed Newsletter. ／Readers' Questionnaire